GambitBio is developing an at-home lateral flow test to screen for the most common cancers, empowering people to take control of their health and reduce the number of cancer-related deaths. Cancer Research Horizons recently interviewed CEO, Tiffany Ma, who co-founded the venture while completing her DPhil at the University of Oxford.
Congratulations to Jingfei Cheng, Holly Eggington, Yi-Jhih Huang, Zhe Huang and Joshua Moore who have been awarded OxCODE funds to attend this year\u2019s major cancer prevention and early detection conferences.
OxCODE primary care researchers recently attended this year's Cancer Research UK Early Diagnosis Conference in Birmingham, which focused on the theme 'Driving Evidence into Practice'.
Proteins linked to cancer can start appearing in people\u2019s blood more than seven years before they\u2019re diagnosed. In the future, it\u2019s possible doctors could use these early warning signs to find and treat cancer much earlier than they\u2019re able to today.
The new method could help people with new-onset diabetes at high-risk of developing pancreatic cancer to be identified more accurately so that they can be monitored.
Oxford and UCL researchers seeking to create the world\u2019s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to \u00a31.7 million from Cancer Research UK and the CRIS Cancer Foundation.
The DeLIVER team will evaluate non-contrast-enhanced MRI and compare it to standard of care ultrasound in a cohort of patients under surveillance for liver cancer.
Professor Jason Davis and team have developed a new sensor to selectively and quantitatively measure p53 autoantibodies in the blood, levels of which are raised in a broad range of cancers.
A computer vision challenge was set to objectively quantify the generalisability of polyp detection and mapping algorithms, and challenge participants to innovate novel methods.
On Tuesday 5th December, the Oxford early cancer detection community gathered at the Mathematical Institute in Oxford to hear some highlights from OxCODE\u2019s research in the past year and to discuss ideas for future projects.
To celebrate the launch of the UK\u2019s first CRUK clinical trials unit dedicated to cancer precision prevention in Oxford, we held a research symposium that highlighted the spectra of Cancer Precision Prevention clinical programmes across the UK.
The Nuffield Department of Primary Care Health Sciences wins an NIHR award for a new HealthTech Research Centre (HRC) to explore innovative Health Technology to enhance community and primary care.
SerenOx Africa, led by Professor Anna Schuh, aims to address diagnostic gaps for common blood disorders through a testing facility for key underserved patient populations in Tanzania. This facility also aims to provide early cancer detection for high-risk patients.
An agreement between Satisfai Health Inc and the University of Oxford will progress the automated assessment of Barrett\u2019s oesophagus with the aim of determining patients most at risk of developing oesophageal cancer.
Congratulations to James Chettle, Masato Inoue and Eoghan Mulholland who have been awarded OxCODE funds to attend this year\u2019s Early Detection of Cancer conference in London.
![\"GambitBio](\"https://www.oxcode.ox.ac.uk/news/featured-interview-with-gambitbio-ceo-and-oxcode-researcher/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n